FindTrial
Sign In

Effect of subanesthetic dose of esketamine on early postoperative depression in elderly patients with sarcopenia

Effect of subanesthetic dose of esketamine on early postoperative depression in elderly patients with sarcopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093533
Enrollment
Unknown
Registered
2024-12-06
Start date
2024-03-28
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression

Interventions

Control group:The patient was given 0.3 mg/kg normal saline
Experimental group:Intravenous injection of 0.3 mg/kg esketamine

Sponsors

Second People's Hospital of Anhui Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age =60 years old; ASA grade I~III; Elderly patients undergoing knee replacement at selected time; Male SMI < 42.6cm2/m2 Female SMI < 30.6cm2/m2.

Exclusion criteria

Exclusion criteria: A history of malignant hyperthermia; Esketamine has contraindication; Patients with a history of severe mental illness, long-term use of antidepressants; BMI > 30kg/m2; Disturbance of consciousness, inability to complete the scale

Design outcomes

Primary

MeasureTime frame
Hamilton scale score;NLRP3 Inflammatory factor;IL-6;Plasma ceramide;—

Countries

China

Contacts

Public ContactWang Yiqiao

Second People's Hospital of Anhui Province

309734607@qq.com+86 158 5694 0528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026